In:
Alzheimer's & Dementia, Wiley, Vol. 15, No. 6 ( 2019-06), p. 764-775
Abstract:
Blood‐based biomarkers of pathophysiological brain amyloid β (Aβ) accumulation, particularly for preclinical target and large‐scale interventions, are warranted to effectively enrich Alzheimer's disease clinical trials and management. Methods We investigated whether plasma concentrations of the Aβ 1–40 /Aβ 1–42 ratio, assessed using the single‐molecule array (Simoa) immunoassay, may predict brain Aβ positron emission tomography status in a large‐scale longitudinal monocentric cohort (N = 276) of older individuals with subjective memory complaints. We performed a hypothesis‐driven investigation followed by a no‐a‐priori hypothesis study using machine learning. Results The receiver operating characteristic curve and machine learning showed a balanced accuracy of 76.5% and 81%, respectively, for the plasma Aβ 1–40 /Aβ 1–42 ratio. The accuracy is not affected by the apolipoprotein E ( APOE ) ε4 allele, sex, or age. Discussion Our results encourage an independent validation cohort study to confirm the indication that the plasma Aβ 1–40 /Aβ 1–42 ratio, assessed via Simoa, may improve future standard of care and clinical trial design.
Type of Medium:
Online Resource
ISSN:
1552-5260
,
1552-5279
DOI:
10.1016/j.jalz.2019.03.009
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
2201940-6
Permalink